Search research articles
Contact Us
Filters
Showing results (31-40 of 77) with videos related to
Page
of 8
Sort By:
British Journal of Cancer
|
July 10, 2020
Early treatment-related neutropenia predicts response to palbociclib
Nicholas P McAndrew, Mark A Dickson, Amy S Clark, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 20, 2021
A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma
Christina V Angeles, Ana Velez, Jordan Rios, et al.
Cancer Research
|
March 13, 2020
Rb and p53-Deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for Survival
George Z Li, Tomoyo Okada, Young-Mi Kim, et al.
Nature Communications
|
September 1, 2016
TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma
Joonil Jung, Joon Sang Lee, Mark A Dickson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 26, 2009
Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors
Dana Rathkopf, Mark A Dickson, Darren R Feldman, et al.
JAMA Oncology
|
April 29, 2016
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial
Mark A Dickson, Gary K Schwartz, Mary Louise Keohan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 19, 2015
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
Troy Z Horvat, Nelly G Adel, Thu-Oanh Dang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 10, 2013
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma
Mark A Dickson, William D Tap, Mary Louise Keohan, et al.
Sarcoma
|
June 16, 2015
Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma
Mark A Dickson, David R D'Adamo, Mary L Keohan, et al.
The Oncologist
|
June 20, 2019
A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor
Evan Rosenbaum, Ciara Kelly, Sandra P D'Angelo, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 77) with videos related to
Sort By:
Page
of 8
British Journal of Cancer
|
July 10, 2020
Early treatment-related neutropenia predicts response to palbociclib
Nicholas P McAndrew, Mark A Dickson, Amy S Clark, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 20, 2021
A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma
Christina V Angeles, Ana Velez, Jordan Rios, et al.
Cancer Research
|
March 13, 2020
Rb and p53-Deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for Survival
George Z Li, Tomoyo Okada, Young-Mi Kim, et al.
Nature Communications
|
September 1, 2016
TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma
Joonil Jung, Joon Sang Lee, Mark A Dickson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 26, 2009
Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors
Dana Rathkopf, Mark A Dickson, Darren R Feldman, et al.
JAMA Oncology
|
April 29, 2016
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial
Mark A Dickson, Gary K Schwartz, Mary Louise Keohan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 19, 2015
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
Troy Z Horvat, Nelly G Adel, Thu-Oanh Dang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 10, 2013
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma
Mark A Dickson, William D Tap, Mary Louise Keohan, et al.
Sarcoma
|
June 16, 2015
Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma
Mark A Dickson, David R D'Adamo, Mary L Keohan, et al.
The Oncologist
|
June 20, 2019
A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor
Evan Rosenbaum, Ciara Kelly, Sandra P D'Angelo, et al.
Page
of 8